The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter, retrospective, observational study of outcomes of treatment for unresectable neuroendocrine tumors G3 of gastroenteropancreatic or unknown primary origin.
 
Taro Shibuki
No Relationships to Disclose
 
Hiroyuki Okuyama
Speakers' Bureau - Novartis Pharmaceuticals, TAIHO Pharma, Astrazeneca, Chugai Pharmaceutical, Incyte Biosciences Japan, Otsuka Pharmaceutical Factory, MIYARISAN Pharmaceutical, MSD, Guardant Health Japan
Research Funding - TAIHO Pharma, Nippon Zoki Pharmaceutical, Toray Medical
 
Naohiro Okano
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte Japan; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Takuro Mizukami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda
Research Funding - Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hiroaki Yanagimoto
No Relationships to Disclose
 
Akihiro Ohba
Honoraria - AstraZeneca; Eisai; Guardant Health; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Zymeworks
Research Funding - Chugai Pharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Emiri Kita
No Relationships to Disclose
 
Noritoshi Kobayashi
Honoraria - Novartis K,K.,Teijin Pharma,Teijin Healthcare,Yakuruto Honsha,PD Radiopharma,Ono Pharma,Taiho Phama,MSD
Research Funding - Novartis (Inst)
 
Satoshi Kobayashi
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Lilly; MSD; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha; Zymeworks
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takaaki Furukawa
No Relationships to Disclose
 
Hiroyuki Asama
No Relationships to Disclose
 
Hidetaka Tsumura
No Relationships to Disclose
 
Ken Kamata
No Relationships to Disclose
 
Kumiko Umemoto
Honoraria - Novartis Pharmaceuticals UK Ltd.; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Yuko Suzuki
No Relationships to Disclose
 
Motohiro Kojima
No Relationships to Disclose
 
Hiroshi Imaoka
Honoraria - AstraZeneca; Boston Scientific; Kaneka Medix; Medico's Hirata; Novartis; SB-KAWASUMI LABORATORIES; SERVIER; Yakult Honsha
Consulting or Advisory Role - SERVIER
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER
Expert Testimony - Kaneka Medix
 
Takeshi Terashima
Speakers' Bureau - Eisai, Bayer, Novartis, Taiho Pharmaceutical, Daiichi Sankyo, AstraZeneca, Chugai Pharma, Ono Pharmaceutical, Bristol-Myers Squibb Japan, Nihon Servier
 
Makoto Ueno
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chiome Bioscience (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Masafumi Ikeda
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Guardant Health; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)